CVD Prevention HubTopic cluster
A growing library of keyword-focused articles on vitamin B12 deficiency, homocysteine, stroke risk, peripheral artery disease, testing strategy, and the limits of supplementation claims.
Target long-tail keywords
Core internal pages
These core pages match the main intent buckets behind the keyword set and keep the blog internally linked to the highest-value money pages.
Blog library
Each post is written in plain English, links back into the main review flow, and includes authority sources for its core claims.
Low vitamin B12 often appears in cardiovascular conversations, but the strongest conclusion is still careful risk interpretation rather than automatic causation.
The biological case is strongest in the homocysteine pathway: low B12 can impair one-carbon metabolism, and hyperhomocysteinemia can injure vascular endothelium.
B12 supplements clearly treat deficiency. The harder question is whether homocysteine lowering changes hard cardiovascular outcomes in routine practice.
Testing makes the most sense in higher-yield groups: people with symptoms, borderline results, risk factors for deficiency, or long-term exposure to medications that lower B12.
Metformin remains a valuable diabetes drug, but its B12 effect is common enough that long-term users should not be treated as if deficiency were rare.
A vegan diet does not automatically equal deficiency, but it does raise the importance of fortified foods, supplements, and periodic review of B12 status.
Stroke is where the B-vitamin trial story becomes more interesting: outcome effects look modest, context dependent, and strongly shaped by background folate exposure.
Peripheral artery disease is one of the more specific vascular contexts where lower B12 levels have been reported, but the evidence still needs a cautious reading.